Scribe Therapeutics Inc.
Organization details
- Legal name
- Scribe Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Alameda
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- SCTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001853921
- EIN
- 82-2157847
Board of directors
-
Behzad Aghazadeh · DirectorSince 2026
-
Benjamin L. Oakes · Director · President, CEOSince 2026
- Since 2026
-
James Dean Watson · DirectorSince 2026
-
Joshua Bleharski · DirectorSince 2026
Chief executives
Board connections
2 of this board's directors also sit on 9 other boards. 9 are in the same sector.
-
ADARx Pharmaceuticals Inc. Same sectorvia Carl L. Gordon
-
Adicet Bio Inc. Same sectorvia Carl L. Gordon
-
ArriVent BioPharma Inc. Same sectorvia Carl L. Gordon
-
BlossomHill Therapeutics Inc. Same sectorvia Carl L. Gordon
-
Compass Therapeutics Inc. Same sectorvia Carl L. Gordon
-
Electra Therapeutics Inc. Same sectorvia Carl L. Gordon
-
Keros Therapeutics Inc. Same sectorvia Carl L. Gordon
-
MBX Biosciences Inc. Same sectorvia Carl L. Gordon
-
Whitehawk Therapeutics Inc. Same sectorvia Behzad Aghazadeh
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $71,344,746
- 9 purchases by 6 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 28, 2026 | Avoro Ventures LLC Director, See Remarks | Open-market purchase | +7,905 | $18.25 | $144,266 |
| Jul 27, 2026 | AH Equity Partners Bio II, L.L.C. 10% owner | Derivative conversion | +2,051,742 | — | — |
| Jul 27, 2026 | Jennifer A. Doudna 10% owner | Derivative conversion | +12,511 | — | — |
| Jul 27, 2026 | Carl L. Gordon Director | Derivative conversion | +348,825 | — | — |
| Jul 27, 2026 | ORBIMED ADVISORS LLC Director | Derivative conversion | +348,825 | — | — |
| Jul 27, 2026 | AH Equity Partners Bio II, L.L.C. 10% owner | Derivative conversion | +697,650 | — | — |
| Jul 27, 2026 | Carl L. Gordon Director | Open-market purchase | +1,000,000 | $15.00 | $15,000,000 |
| Jul 27, 2026 | ORBIMED ADVISORS LLC Director | Open-market purchase | +1,000,000 | $15.00 | $15,000,000 |
| Jul 27, 2026 | AH Equity Partners Bio II, L.L.C. 10% owner | Open-market purchase | +333,333 | $15.00 | $4,999,995 |
| Jul 24, 2026 | Avoro Ventures LLC Director, See Remarks | Open-market purchase | +2,333,333 | $15.00 | $34,999,995 |
| Jul 24, 2026 | Avoro Ventures LLC Director, See Remarks | Open-market purchase | +50,000 | $22.31 | $1,115,500 |
| Jul 23, 2026 | Svetlana Lucas Officer (Chief Business Officer) | Open-market purchase | +3,000 | $15.00 | $45,000 |
| Jul 23, 2026 | Parrot David Officer (Chief Financial Officer) | Open-market purchase | +1,333 | $15.00 | $19,995 |
| Jul 23, 2026 | Parrot David Officer (Chief Financial Officer) | Open-market purchase | +1,333 | $15.00 | $19,995 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Scribe Therapeutics Inc.
Who is the CEO of Scribe Therapeutics Inc.?
Benjamin L. Oakes has been Scribe Therapeutics Inc.'s President, CEO since July 2026.
How many directors are on Scribe Therapeutics Inc.'s board?
Scribe Therapeutics Inc.'s board has 5 directors: Behzad Aghazadeh, Benjamin L. Oakes, Carl L. Gordon, James Dean Watson and Joshua Bleharski.
Are Scribe Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Scribe Therapeutics Inc. insiders bought $71.3 million of shares in 9 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="scribe-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.